From Rational In Silico Design to High-Performance Microbial Cell Factories. Bacillus subtilis is a premier industrial "chassis" known for its exceptional protein secretion capacity and GRAS (Generally Recognized as Safe) status. CD Biosynsis provides professional Bacillus subtilis Genome Editing and Metabolic Engineering Solutions, integrating advanced genome-scale modeling with next-generation "markerless" editing tools. We empower our clients to accelerate the development of high-yield strains for enzymes, vitamins, and high-value natural products through precise, data-driven engineering.
Get a Technical QuoteWe offer a comprehensive "Design-Build-Test" workflow, transforming wild-type strains into optimized industrial producers through a combination of computational modeling and precision genome engineering.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Rational Design | GSMM & Enzyme-Constrained Modeling | Predictive targeting & bottleneck identification | Metabolic flux map + Engineering roadmap |
| Markerless Editing | Inducible Dre-rox & CRISPR Platforms | "Clean" industrial strains (No foreign markers) | Verified scarless mutants + Sequencing data |
| Chassis Engineering | Physiological & Competence Tuning | Improving host robustness & production stability | Optimized "Super-Host" chassis strains |
| Metabolic Rewiring | BGC Discovery & Pathway Reconstruction | Maximizing titers of natural products/enzymes | Engineered production strains + Titer analysis |
1. In Silico Simulation
2. Strategic Design
3. Genome Engineering
4. Pilot Assessment
Building and analyzing genome-scale or enzyme-constrained metabolic models to identify optimal gene targets.
Detailed evaluation of metabolic flux to avoid trial-and-error.
Formulating the engineering roadmap, including selection of markerless tools and regulatory elements.
Formal project proposal and Mutual NDA signing.
Executing precise edits (knockouts, knock-ins, or pathway integration) using scarless and orthogonal systems.
Simultaneous multi-locus engineering for complex biosynthetic clusters.
Characterizing engineered strains for production stability and metabolite titers in simulated fermentation.
Final delivery of optimized "Super-Host" chassis and characterization reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. Please note that these studies represent established academic benchmarks and were not conducted by our company.
Utilizing Genome-Scale Metabolic Models (GSMM), academic research has successfully predicted essential gene targets for the biosynthesis of complex lipopeptides such as Fengycin. By integrating genomic data with metabolic networks, rational design enabled the strategic knockout and overexpression of key metabolic nodes, leading to a significant increase in antibiotic titers through data-driven pathway engineering.
(Reference: Chtioui et al., 2021)
To achieve superior accuracy in metabolic engineering, researchers have developed advanced models such as ecBSU1. Unlike traditional GSMMs, enzyme-constrained models incorporate enzyme kinetic data and protein abundance limits. This allows for more reliable in silico simulations of B. subtilis behavior, ensuring that genomic edits translate more accurately into predicted phenotypic improvements in the laboratory.
(Reference: Wu et al., 2023)
The shift toward markerless (scarless) genome editing is exemplified by the development of inducible and orthogonal Dre-rox systems. This tool allows for high-efficiency edits without the continuous expression of exogenous nucleases or the presence of antibiotic resistance markers in the final genome. This "clean" engineering approach is critical for creating industrial strains destined for large-scale production where safety is paramount.
(Reference: Ly et al., 2025)
Modern metabolic engineering emphasizes that host-specific traits are as important as the target pathway. Technical advancements highlight how editing host characteristics—such as enhancing DNA competence or reducing biofilm interference—can transform B. subtilis into a "Super-Host" for the discovery and large-scale biosynthesis of diverse gene clusters (BGCs).
(Reference: Put et al., 2024)
Ready to design your B. subtilis engineering strategy?
Contact Us1. What is the benefit of an "Enzyme-Constrained" model (ecModel)?
Standard models only look at gene presence. ecModels (like ecBSU1) account for enzyme kinetics and protein capacity, leading to much more accurate predictions of how much product a cell can actually synthesize.
2. Why is "Markerless" editing required for industrial strains?
Industrial strains in the food and pharma sectors must often be "clean." Markerless editing ensures no antibiotic resistance markers remain in the final strain, ensuring genetic stability and safety.
3. Can you optimize B. subtilis to express large biosynthetic gene clusters (BGCs)?
Yes. Through a combination of chassis engineering to improve host compatibility and precision integration tools, we can stably incorporate large, complex pathways into the B. subtilis genome.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.